Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

BACKGROUND: The benefit of adjuvant chemotherapy in invasive lobular carcinoma (ILC) is still unclear. The objective of the current study was to elucidate the effectiveness of adjuvant chemotherapy in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, pT1b-c/N0...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Guangfu, Hu, Guangxia, Zhang, Chengjiao, Lin, Xiaoyan, Shan, Ming, Yu, Yanmin, Lu, Yongwei, Niu, Ruijie, Ye, Hui, Wang, Cheng, Xu, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035707/
https://www.ncbi.nlm.nih.gov/pubmed/32085753
http://dx.doi.org/10.1186/s12885-020-6614-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035707/
https://www.ncbi.nlm.nih.gov/pubmed/32085753
http://dx.doi.org/10.1186/s12885-020-6614-0

Ejemplares similares